BMS attempts to distance itself from fraud allegations
October 31, 2003Bristol-Myers Squibb is attempting to draw a line under allegations of fraud and financial misconduct by downgrading earnings as far …
Industry reputation under fire at home and abroad
October 31, 2003Continuing conflict over access to medicines in developing countries and growing distrust of big pharma in domestic markets is threatening …
Germany delay undermines Crestor confidence
October 31, 2003AstraZeneca's cholesterol treatment Crestor has been dealt a serious blow following Germanys withdrawal from a pan-European approval process.Germany, the EU's …
Parliamentary showdown for foundation trust plans
October 31, 2003Health Secretary Alan Milburn has published the final plans for the controversial foundation trusts with the promise that all NHS …
Smallpox vaccine puts Acambis into profit
October 31, 2003Vaccine company Acambis has joined rivals PowderJect and Celltech in the elite group of profitable UK biotech companies.The company recorded …
Shire appoints Emmens as new chief executive
October 31, 2003Matthew Emmens, former head of Merck KGaA's global prescription group, has been appointed as the new Chief Executive of Shire …
Paediatric trials to be mandatory in US
October 31, 2003Plans to make clinical trials mandatory for all drugs intended for children are progressing in the US.The Paediatric Research Equity …
Foundation status offered to 38 more trusts
October 31, 2003A further 38 hospital have been invited to apply for foundation trust status after winning three stars in the recent …
Doubts over pipeline cloud Aventis results
October 31, 2003Aventis may struggle to replace revenue from its ageing blockbusters despite a strong performance in the second quarter, according to …
BMS and Lilly exceed expectations
October 31, 2003Strong sales of established and new products in the second quarter saw both Bristol-Myers Squibb and Eli Lilly beat analysts' …
Smooth transition from old to new for AstraZeneca
October 31, 2003Growth in new products are helping to plug the sizeable gap left by three of AstraZeneca's ageing blockbusters Prilosec (Losec), …
Weak dollar contains Sanofi growth
October 31, 2003The weakness of the US dollar more than halved Sanofi-Synthelabo's earnings in the first half of this year, but disguised …
Heart failure guidelines recommend ACE inhibitors
October 31, 2003ACE inhibitors have been recommended as first line treatment for chronic heart failure as part of a comprehensive set of …
Media training company launched
October 31, 2003A new training agency specialising in preparing pharmaceutical spokespeople to deal with modern media techniques has been launched.Asparagus Media, set …
Industry could gain access to yellow card data
October 31, 2003The pharmaceutical industry could be granted access to data from the UK's Yellow Card adverse effect warning system to assist …
Celebrex to gain orphan drug indication
October 31, 2003Pfizer's blockbuster arthritis drug Celebrex is set to gain a European orphan drug licence for the treatment of a rare …
Challenging second quarter for big pharma
October 31, 2003Generic competition and wholesaler de-stocking are among the problems besetting two of the industry's biggest hitters, GlaxoSmithKline and AstraZeneca.Deutsche Bank …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
